Presentation

Vicore Pharma is a drug development company focused on rare and deadly lung disorders where there is currently no satisfactory treatment. The firm has created and patented a unique collection of small molecules that stimulate the AT2 receptor within the Renin Angiotensin System (RAS). C21 (VP01) has been granted orphan drug status by both EMA (Europe) and FDA (U.S.), the drug is currently under Phase 2 trial in IPF and Phase 3 in COVID-19. Apart from C21, Vicore also has a rich pipeline: VP02 (Thalidomide),VP03 (new AT2R agonists) and VP04 (Digital Therapeutics).

Recent highlights
In February 2022, Vicore reported data in open-label phase 2 trial within idiopathic pulmonary fibrosis (IPF) patients. Early data, yet with mean lung capacity increases of +751 mL at week 36, the data was unprecedented and strong enough to trigger an early readout and the planning of the next, potentially pivotal study.

Outlook
We expect follow-up data from C21 in IPF will be published in Q3 2022. Vicore just also announced first healthy volunteer was dosed with C106 in a phase 1 trial. C106 is an angiotensin II type 2 receptor agonist (ATRAG) developed by the VP03 platform with topline data expected in Q1 2023.